Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study
Open Access
- 10 February 2026
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 40 (3) , 630-637
Abstract
With increasing survival in acute lymphoblastic leukemia (ALL), long-term toxicities have become a critical aspect. A novel measure, designated Severe Toxicity-free survival (STFS), was developed through international consensus to integrate the most severe, symptomatic organ toxicities in outcome evaluation. This measure has not been applied to real-world data before. We assessed the incidence of 21 predefined Severe Toxicities in a nationwide cohort of 506 ALL patients aged 1–45 years treated according to the NOPHO ALL2008 protocol. At five years, event-free survival was 84.4% (95% CI: 81.3–87.7%) and Severe Toxicity-event-free survival was 78.4% (95% CI: 74.9–82.1%), with significantly lower values in adults (aged 18–45 years) than children (61.6% [52.6–72.2%] vs 82.4% [78.8–86.2%]; log-rank p < 0.001). The most common Severe Toxicities were severe osteonecrosis limiting activities of daily function ( N = 20) and disabling paralytic and neuropathic conditions ( N = 16). Exploratory analyses showed that 10–17-year-olds had the highest risk of Severe Toxicities similar to that of adults. These findings highlight a burden of severe, long-term toxicities in ALL survivors overlooked by traditional outcome measures, also following frontline therapy only. STFS should be incorporated in future trials for meaningful outcome evaluation and international comparisons across treatment strategies.Keywords
Funding Information
- Aase og Ejnar Danielsens Fond (22-10-0382)
- Eva og Henry Frænkels Mindefond (-)
This publication has 35 references indexed in Scilit:
- Acute lymphocytic leukaemiaThe Lancet, 2025
- Children with cancer and their cardiorespiratory fitness and physical function—the long-term effects of a physical activity program during treatment: a multicenter non-randomized controlled trialJournal of Cancer Survivorship, 2023
- Late effects of cancer in children, teenagers and young adults: Population-based study on the burden of 183 conditions, in-patient and critical care admissions and years of life lostThe Lancet Regional Health - Europe, 2021
- Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemiaThe Lancet Haematology, 2021
- The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort StudyThe Lancet Haematology, 2019
- Insulin‐dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemiaPediatric Blood & Cancer, 2018
- Treatment of young adults with Philadelphia‐negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper‐CVAD vs. pediatric‐inspired regimensAmerican Journal of Hematology, 2018
- The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)The Lancet, 2017
- Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemiaLeukemia, 2017
- Survivors of childhood and adolescent cancer: life-long risks and responsibilitiesNature Reviews Cancer, 2013